Factors affecting PARP inhibitor use as maintenance treatment in platinum-sensitive recurrent ovarian cancer

被引：0
|
作者：
Valentine, Mark [1 ]
Perhanidis, Jessica [2 ]
Hawkes, Carol [2 ]
Thaker, Premal [1 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO 63110 USA
[2] GlaxoSmithKline, Waltham, MA USA
来源：
GYNECOLOGIC ONCOLOGY | 2021年 / 162卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
291
引用
收藏
页码：S158 / S158
页数：1
相关论文
共 50 条
  • [1] Factors affecting PARP inhibitor use as maintenance treatment in platinum-sensitive recurrent ovarian cancer
    Hanker, L.
    Valentine, M. C.
    Perhanidis, J. A.
    Hawkes, C.
    Thaker, P. H.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 241 - 241
  • [2] Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
    Guerra Alia, Eva Maria
    Sempere Ortega, Cayetano
    Cortes Salgado, Alfonso
    Sanchez Martinez, Concepcion
    Galindo Alvarez, Julio
    Perez Miez, Belen
    CASE REPORTS IN ONCOLOGY, 2019, 12 (02): : 447 - 455
  • [3] PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis
    Smith, Haller J.
    Haygood, Christen L. Walters
    Arend, Rebecca C.
    Leath, Charles A., III
    Straughn, Michael, Jr.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 59 - 62
  • [4] Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
    Mirza, M. R.
    Monk, B. J.
    Herrstedt, J.
    Oza, A. M.
    Mahner, S.
    Redondo, A.
    Fabbro, M.
    Ledermann, J. A.
    Lorusso, D.
    Vergote, I.
    Ben-Baruch, N. E.
    Marth, C.
    Madry, R.
    Christensen, R. D.
    Berek, J. S.
    Dorum, A.
    Tinker, A. V.
    du Bois, A.
    Gonzalez-Martin, A.
    Follana, P.
    Benigno, B.
    Rosenberg, P.
    Gilbert, L.
    Rimel, B. J.
    Buscema, J.
    Balser, J. P.
    Agarwal, S.
    Matulonis, U. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22): : 2154 - 2164
  • [5] Utilization of maintenance therapy for platinum-sensitive recurrent ovarian cancer
    Wall, J. A.
    Davis, A. M.
    Beer, H.
    Foxall, M.
    Londono, A. I.
    McGwin, G.
    Leath, C. A., III
    Arend, R. C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 115 - 115
  • [6] PARP inhibitors as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: Can we afford it?
    Smith, H. J.
    Haygood, C. L. Walters
    Arend, R. C.
    Leath, C. A., III
    Straughn, J. M., Jr.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 9 - 9
  • [7] The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer
    Lorusso, Domenica
    Fontanella, Caterina
    Maltese, Giuseppa
    Lepori, Stefano
    Tripodi, Elisa
    Bogani, Giorgio
    Raspagliesi, Francesco
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (06) : 687 - 696
  • [8] Concerns with "maintenance chemotherapy" for patients with recurrent platinum-sensitive ovarian cancer
    Markman, M
    GYNECOLOGIC ONCOLOGY, 1999, 73 (03) : 469 - 470
  • [9] Maintenance chemotherapy among patients with platinum-sensitive recurrent ovarian cancer
    Yang Qiuan
    Zhao Weiping
    Wang QingweiThe Cancer Center of the Affiliated Hospital of Shandong Medical University
    现代妇产科进展, 1999, (04) : 394 - 395
  • [10] Cost-effectiveness of homologous recombination defect testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer
    Alvarez-Secord, A.
    Barnett, J.
    Ledermann, J.
    Peterson, B.
    Myers, E.
    Havrilesky, L.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S92 - S93
12345